SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2007. Revenues for the quarter were $25.8 million, compared to $3.1 million for the same period in 2006. Revenues and net income for the fourth quarter were positively impacted by recognition of revenue associated with up-front and milestone payments from XenoPort’s collaborations with GlaxoSmithKline, Astellas Pharma Inc. and Xanodyne Pharmaceuticals, Inc. Net income for the fourth quarter was $2.5 million, compared to a net loss of $18.6 million for the same period in 2006. At December 31, 2007, XenoPort had cash and cash equivalents and short-term investments of $160.1 million.
